Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

With a Rise in Animal-Human Organ Transplants, a Drugmaker Aims for a New Standard of Care

Key Takeaway: The article discusses the rise in animal-human organ transplants and how a drugmaker is positioning itself to set a new standard of care in this emerging field. It highlights the transformative potential of these transplants for patients in need of organ replacements. The company aims to leverage advancements in this area to improve patient outcomes significantly.
Price reaction · baseline $1.69 (2024-04-12 close) · 1 other ELDN headline(s) in the window, move may be shared
day 0 close
-3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Increased focus on animal-human organ transplants.
  • Potential for establishing a new standard of care.
  • Emphasis on transforming lives through innovative solutions.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is the focus of the drugmaker mentioned?

The drugmaker is focusing on establishing a new standard of care in animal-human organ transplants.

How do animal-human organ transplants benefit patients?

These transplants have the potential to transform lives by providing necessary organ replacements.

Last updated: Apr 13, 2024